Risperdal

Find a Lawyer in Your State

Need Help?

Contact Us Today

I agree that submitting this form and the information contained within does not establish an attorney client relationship.

ATTORNEY ADVERTISING -
Flood Law Group, LLP
1101 Pennsylvania Avenue
Suite 600
Washington, DC 20004
(888) 334-2084

Privacy protected. All information held in the strictest confidence.

Risperdal

Risperdal was FDA approved to help treat symptoms of schizophrenia. The popularity of Risperdal has continued to grow over the years and doctors have been prescribing Risperdal for behavioral and conduct disorders. On April 10, 2003, Risperdal maker Johnson & Johnson made an announcement that they would be sending out thousands of letters to doctors warning of the possibly increased risk of suffering stroke in elderly Risperdal patients.

The Risperdal announcement indicated that there was a more dangerous risk in treating a wider range of patients with the powerful psychotic drug. Various Risperdal clinical trials show that stroke or stroke-like events, including blood clots or hemorrhages can occur with Risperdal use, which is troubling. In October 2002, Risperdal makers issued a similar stroke warning to Canadian physicians. Cited in the Risperdal warning were 37 reports of stroke or stroke-like events, including 16 deaths. Risperdal makers say they will change Risperdal package-insert labels to include more specific Risperdal risks.

Defective Drugs Breaking News

"Risperdal Manufacturer Admits Deception"

Janssen Pharmaceutic Products, the makers of the anti-psychotic drug Risperdal, sent a letter to the health care community outlining the potential health risks associated with the medication.

This action is in compliance with the FDA''s re...

» Read More

"Studies Show Zyprexa, Risperdal May Have Inferior Effects When Compared to Clozapine"

According to new data, once an effective dose has been reached Zyprexa and Risperdal have been shown to have inferior results in terms of anti-aggressive effects compared to cl...

» Read More